Tejas Patil

机构：University of Colorado Cancer Center, University of Colorado Denver · ORCID：0000-0003-4389-1010

发表论文 183 篇 · 总被引 3758 次 · h-index 26

代表论文

• NCCN Guidelines® Insights: Non–Small Cell Lung Cancer, Version 7.2025 (2025 · Journal of the National Comprehensive Cancer Network · 被引 65)
• Thymomas and Thymic Carcinomas, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology (2025 · Journal of the National Comprehensive Cancer Network · 被引 31)
• Enfortumab vedotin in patients with advanced non-small cell lung cancer after disease progression on platinum- and PD-1/PD-L1 inhibitor-containing regimens: Phase 2 international multicenter EV-202 study (2025 · European Journal of Cancer · 被引 6)
• Osimertinib vs. Afatinib in 1L therapy of atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC): A multi-institution, real-world survival analysis (2025 · Lung Cancer · 被引 6)
• Multi-Institution Analysis of Tarlatamab for the Treatment of EGFR -Mutant Transformed Small Cell Lung Cancer (2025 · JCO Precision Oncology · 被引 4)
• Abstract CT109: A first-in-human phase 1 study of LY4050784, an oral, potent, and selective SMARCA2 inhibitor, in patients with advanced solid tumors with SMARCA4 alterations (Trial in Progress) (2025 · Cancer Research · 被引 4)